Secukinumab provides improvements in health-related quality of life in patients with psoriatic arthritis, regardless of the time since diagnosis: pooled results from the Secukinumab phase 3 trial program

No Thumbnail Available
File version
Author(s)
Strand, Vibeke
Fitzgerald, Oliver
Coates, Laura C
Walsh, Jessica A
Canete, Juan D
Nash, Peter
Davenport, Eric
Pricop, Luminita
Hustache, Gregory
Gilloteau, Isabelle
Yocolly, Aurore
Augustin, Matthias
Griffith University Author(s)
Primary Supervisor
Other Supervisors
Editor(s)
Date
2019
Size
File type(s)
Location

Madrid, Spain

License
Journal Title
Conference Title

Annals of the Rheumatic Diseases

Book Title
Edition
Volume

78

Issue

Suppl 2

Thesis Type
Degree Program
School
Publisher link
Patent number
Funder(s)
Grant identifier(s)
Rights Statement
Rights Statement
Item Access Status
Note
Access the data
Related item(s)
Subject

Clinical sciences

Immunology

Science & Technology

Life Sciences & Biomedicine

Rheumatology

Persistent link to this record
Citation

Strand, V; Fitzgerald, O; Coates, LC; Walsh, JA; Canete, JD; Nash, P; Davenport, E; Pricop, L; Hustache, G; Gilloteau, I; Yocolly, A; Augustin, M, Secukinumab provides improvements in health-related quality of life in patients with psoriatic arthritis, regardless of the time since diagnosis: pooled results from the Secukinumab phase 3 trial program, Annals of the Rheumatic Diseases, 2019, 78 (Suppl 2), pp. 1860-1861